These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22519914)

  • 1. The need for worldwide policy and action plans for rare diseases.
    Forman J; Taruscio D; Llera VA; Barrera LA; Coté TR; Edfjäll C; Gavhed D; Haffner ME; Nishimura Y; Posada M; Tambuyzer E; Groft SC; Henter JI;
    Acta Paediatr; 2012 Aug; 101(8):805-7. PubMed ID: 22519914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The European Union Policy in the Field of Rare Diseases.
    Moliner AM; Waligora J
    Adv Exp Med Biol; 2017; 1031():561-587. PubMed ID: 29214592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of 11 national policies for rare diseases in the context of key patient needs.
    Dharssi S; Wong-Rieger D; Harold M; Terry S
    Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why we should care about ultra-rare disease.
    Harari S
    Eur Respir Rev; 2016 Jun; 25(140):101-3. PubMed ID: 27246584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Legal assessment of current situation on orphan patients in Lithuania.
    Spokiene I
    Medicina (Kaunas); 2008; 44(8):571-6. PubMed ID: 18791333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Access to information supporting availability of medicines for patients suffering from rare diseases looking for possible treatments: the EuOrphan Service.
    Stakisaitis D; Spokiene I; Juskevicius J; Valuckas KP; Baiardi P
    Medicina (Kaunas); 2007; 43(6):441-6. PubMed ID: 17637514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National Organization for Rare Disorders (NORD): providing advocacy for people with rare disorders.
    Putkowski S
    NASN Sch Nurse; 2010 Jan; 25(1):38-41. PubMed ID: 20440954
    [No Abstract]   [Full Text] [Related]  

  • 9. Tackling rare diseases at European level: why do we need a harmonized framework?
    Taruscio D; Trama A; Stefanov R
    Folia Med (Plovdiv); 2007; 49(1-2):59-67. PubMed ID: 18018471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparing for the Future of Rare Diseases.
    Groft SC; Posada de la Paz M
    Adv Exp Med Biol; 2017; 1031():641-648. PubMed ID: 29214596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
    Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K
    J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare Diseases: Joining Mainstream Research and Treatment Based on Reliable Epidemiological Data.
    Groft SC; Posada de la Paz M
    Adv Exp Med Biol; 2017; 1031():3-21. PubMed ID: 29214563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Policy framework for rare disease health disparities.
    Holtzclaw Williams P
    Policy Polit Nurs Pract; 2011 May; 12(2):114-8. PubMed ID: 21486874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Participant-funded clinical trials on rare diseases].
    Dal-Ré R; Palau F; Guillén-Navarro E; Ayuso C
    An Pediatr (Engl Ed); 2020 Oct; 93(4):267.e1-267.e9. PubMed ID: 32499195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brexit and rare diseases: big risk, bigger opportunity?
    Hyry HI; Cox TM; Roos JC
    Curr Med Res Opin; 2017 Apr; 33(4):783-784. PubMed ID: 28100081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hungarian national plan and strategy for rare diseases].
    Kosztolányi G
    Orv Hetil; 2014 Mar; 155(9):325-8. PubMed ID: 24566695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The stakes of pre- and post-market authorization development and clinical assessment].
    Schwebig A
    Presse Med; 2012 May; 41 Suppl 1():S6-8. PubMed ID: 22483770
    [No Abstract]   [Full Text] [Related]  

  • 18. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [RARE DISEASES DTC: DIAGNOSIS, TREATMENT AND CARE].
    Mendlovic J; Barash H; Yardeni H; Banet-Levi Y; Yonath H; Raas-Rothschild A
    Harefuah; 2016 Apr; 155(4):241-4, 253. PubMed ID: 27323543
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.